(HSIC) Henry Schein - Overview
Stock: Dental Supplies, Medical Supplies, Equipment, Software, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 31.6% |
| Relative Tail Risk | -5.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -13.44 |
| Character TTM | |
|---|---|
| Beta | 0.577 |
| Beta Downside | 0.406 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.45% |
| CAGR/Max DD | -0.08 |
Description: HSIC Henry Schein January 07, 2026
Henry Schein Inc. (NASDAQ: HSIC) distributes a broad portfolio of health-care products and services to office-based dental and medical practices, laboratories, ambulatory surgery centers, and government or institutional clinics worldwide. Its operations are organized into three segments: Global Distribution & Value-Added Services, Global Specialty Products, and Global Technology, covering everything from dental consumables and equipment to pharmaceuticals, vaccines, and practice-management software.
According to the company’s FY 2023 filing, HSIC generated ≈ $9.1 billion in revenue, with a 6.4 % operating margin and adjusted EPS of $5.23. The firm reported a 5-year compounded annual revenue growth rate of roughly 8 %, driven by strong demand for digital dentistry tools and recurring consumable sales. Cash flow from operations exceeded $1.2 billion, supporting its non-recourse financing program for practitioner loans.
Key macro-drivers for HSIC include the aging U.S. and global populations, which raise demand for dental and orthopedic procedures, and the continued shift toward high-margin digital and implant-based treatments. Additionally, the broader health-care distribution sector benefits from consolidation trends and the need for integrated supply-chain solutions, which favor large, diversified distributors like Henry Schein.
For a deeper quantitative analysis, you might explore ValueRay’s platform, which aggregates real-time financial metrics and peer comparisons for HSIC and its industry peers.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 391.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.72 > 1.0 |
| NWC/Revenue: 9.63% < 20% (prev 9.74%; Δ -0.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 535.0m > Net Income 391.0m |
| Net Debt (3.31b) to EBITDA (980.0m): 3.37 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.0m) vs 12m ago -4.74% < -2% |
| Gross Margin: 29.20% > 18% (prev 0.30%; Δ 2890 % > 0.5%) |
| Asset Turnover: 119.2% > 50% (prev 117.9%; Δ 1.37% > 0%) |
| Interest Coverage Ratio: 4.62 > 6 (EBITDA TTM 980.0m / Interest Expense TTM 146.0m) |
Altman Z'' 2.68
| A: 0.11 (Total Current Assets 4.39b - Total Current Liabilities 3.15b) / Total Assets 11.10b |
| B: 0.30 (Retained Earnings 3.38b / Total Assets 11.10b) |
| C: 0.06 (EBIT TTM 675.0m / Avg Total Assets 10.85b) |
| D: 0.51 (Book Value of Equity 3.15b / Total Liabilities 6.20b) |
| Altman-Z'' Score: 2.68 = A |
Beneish M -3.00
| DSRI: 1.01 (Receivables 1.74b/1.66b, Revenue 12.94b/12.50b) |
| GMI: 1.01 (GM 29.20% / 29.62%) |
| AQI: 0.99 (AQ_t 0.52 / AQ_t-1 0.53) |
| SGI: 1.04 (Revenue 12.94b / 12.50b) |
| TATA: -0.01 (NI 391.0m - CFO 535.0m) / TA 11.10b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of HSIC shares?
Over the past week, the price has changed by +5.62%, over one month by +1.49%, over three months by +13.79% and over the past year by -0.16%.
Is HSIC a buy, sell or hold?
- StrongBuy: 3
- Buy: 4
- Hold: 8
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the HSIC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78.1 | -2% |
| Analysts Target Price | 78.1 | -2% |
| ValueRay Target Price | 85.1 | 6.7% |
HSIC Fundamental Data Overview February 05, 2026
P/E Forward = 13.9665
P/S = 0.6855
P/B = 2.5615
P/EG = 1.6424
Revenue TTM = 12.94b USD
EBIT TTM = 675.0m USD
EBITDA TTM = 980.0m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 1.02b USD (from shortTermDebt, last quarter)
Debt = 3.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.31b USD (from netDebt column, last quarter)
Enterprise Value = 12.17b USD (8.87b + Debt 3.44b - CCE 136.0m)
Interest Coverage Ratio = 4.62 (Ebit TTM 675.0m / Interest Expense TTM 146.0m)
EV/FCF = 31.87x (Enterprise Value 12.17b / FCF TTM 382.0m)
FCF Yield = 3.14% (FCF TTM 382.0m / Enterprise Value 12.17b)
FCF Margin = 2.95% (FCF TTM 382.0m / Revenue TTM 12.94b)
Net Margin = 3.02% (Net Income TTM 391.0m / Revenue TTM 12.94b)
Gross Margin = 29.20% ((Revenue TTM 12.94b - Cost of Revenue TTM 9.16b) / Revenue TTM)
Gross Margin QoQ = 28.69% (prev 29.38%)
Tobins Q-Ratio = 1.10 (Enterprise Value 12.17b / Total Assets 11.10b)
Interest Expense / Debt = 1.10% (Interest Expense 38.0m / Debt 3.44b)
Taxrate = 20.44% (28.0m / 137.0m)
NOPAT = 537.0m (EBIT 675.0m * (1 - 20.44%))
Current Ratio = 1.40 (Total Current Assets 4.39b / Total Current Liabilities 3.15b)
Debt / Equity = 1.02 (Debt 3.44b / totalStockholderEquity, last quarter 3.36b)
Debt / EBITDA = 3.37 (Net Debt 3.31b / EBITDA 980.0m)
Debt / FCF = 8.65 (Net Debt 3.31b / FCF TTM 382.0m)
Total Stockholder Equity = 3.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 391.0m / Total Assets 11.10b)
RoE = 11.58% (Net Income TTM 391.0m / Total Stockholder Equity 3.38b)
RoCE = 12.21% (EBIT 675.0m / Capital Employed (Equity 3.38b + L.T.Debt 2.15b))
RoIC = 8.58% (NOPAT 537.0m / Invested Capital 6.26b)
WACC = 6.04% (E(8.87b)/V(12.31b) * Re(8.04%) + D(3.44b)/V(12.31b) * Rd(1.10%) * (1-Tc(0.20)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.78%
[DCF Debug] Terminal Value 84.22% ; FCFF base≈405.6m ; Y1≈353.7m ; Y5≈284.8m
Fair Price DCF = 42.17 (EV 8.27b - Net Debt 3.31b = Equity 4.96b / Shares 117.7m; r=6.04% [WACC]; 5y FCF grow -15.64% → 2.90% )
EPS Correlation: -38.09 | EPS CAGR: -48.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: 17.92 | Revenue CAGR: 0.07% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.27 | Chg30d=-0.001 | Revisions Net=+2 | Analysts=12
EPS next Year (2026-12-31): EPS=5.28 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+7.7% | Growth Revenue=+3.4%